Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mycophenolate Mofetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 19/20 | 0.69 |
| ▸ | IMPDH1 known ✓ | P20839 | 14/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mycophenolate Mofetil SCHEMBL2257852 | 1.00 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL3016439 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL10262894 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29378681 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29645056 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL23581135 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL4195 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL28390 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL218782 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29571382 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116133639-A | Formulations and methods for treating inflammatory diseases | 维奥梅治疗公司 | 2023-05-16 | — | — | CN | claimed |
| US-20130252997-A1 | TREATING UNWANTED OCULAR CONDITION USING AN ASCOMYCIN MACROLACTAM | ALLERGAN, INC. (US) | 2013-09-26 | — | — | US | claimed |
| US-20100204470-A1 | METHOD FOR SALT PREPARATION | SANDOZ AG | 2010-08-12 | — | — | US | claimed |
| US-20090180986-A1 | TREATING UNWANTED OCULAR CONDITIONS USING AN ASCOMYCIN MACROLACTAM | ALLERGAN, INC. | 2009-07-16 | — | — | US | claimed |
| EP-2032521-A2 | NEW METHOD FOR SALT PREPARATION | Sandoz AG (CH) | 2009-03-11 | — | — | EP | claimed |
| WO-2008000418-A2 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2008-01-03 | — | — | WO | claimed |
| EP-0724581-B1 | CRYSTALLINE ANHYDROUS MYCOPHENOLATE MOFETIL AND INTRAVENOUS FORMULATION THEREOF | SYNTEX INC (US) | 1998-11-18 | — | — | EP | claimed |
| EP-0724581-A1 | CRYSTALLINE ANHYDROUS MYCOPHENOLATE MOFETIL AND INTRAVENOUS FORMULATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995007902-A1 | CRYSTALLINE ANHYDROUS MYCOPHENOLATE MOFETIL AND INTRAVENOUS FORMULATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1995-03-23 | — | — | WO | claimed |
| EP-4458953-A2 | METHODS FOR STEM CELL TRANSPLANTATION | The UAB Research Foundation (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-3340997-B1 | METHODS FOR STEM CELL TRANSPLANTATION | UAB RES FOUND (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-116133639-A | Formulations and methods for treating inflammatory diseases | 维奥梅治疗公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-4948793-A | Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof | SYNTEX (U.S.A.) INC. (US) | 1990-08-14 | — | — | US | disclosed |
| US-4868153-A | IMMUNOSUPPRESSION | SYNTEX (U.S.A.) INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4808592-A | ANTIBODY INHIBITORS; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4786637-A | IMMUNOSUPPRESSIVE AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0281713-A1 | Morpholinoethylester of mycophenolic acid and derivatives thereof, their preparation and use in pharmaceutical compositions | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4753935-A | ANTIBODY INHIBITORS; ANTITUMOR, ANTIINFLAMMATORY, ANTIVIRAL AND ANTIPSORIASIS AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252997-A1 | TREATING UNWANTED OCULAR CONDITION USING AN ASCOMYCIN MACROLACTAM | ABHD12, ERG28, HDAC6 | IMPDH2 749/4885IMPDH1 874/4885ALDH1A1 1531/4885 |
| US-20090180986-A1 | TREATING UNWANTED OCULAR CONDITIONS USING AN ASCOMYCIN MACROLACTAM | HDAC6, MALT1, ERG28 | IMPDH2 859/4885IMPDH1 979/4885ALDH1A1 1406/4885 |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | UACA, TNF, TPMT | IMPDH2 575/4885IMPDH1 469/4885ALDH1A1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.